Media & Press Updates

What Happened in 2016


Evestra Receives Gates Foundation Grant

January 18, 2016

Evestra, Inc. announced today that it has received a grant from the Bill & Melinda Gates Foundation to advance research on a technology that could lead to long-acting injectable fertility control for women in underserved regions such as Sub-Saharan Africa, where less than 20 percent of women use modern fertility control.
“We share the Gates Foundation’s concern that more than 220 million women who don’t want to get pregnant and live in developing countries lack access to fertility control and voluntary family planning information and services,” said Ze’ev Shaked, Ph.D., Evestra’s President and CEO. “We applaud the Foundation’s commitment to solving this problem. Evestra’s expertise and innovative approach to women’s health issues will greatly benefit the Gates Foundation’s efforts. We’re are excited to work with them.”
Evestra is applying its proprietary prodrug platform technology to the development of the product, said Klaus Nickisch, Ph.D., Evestra’s Chief Scientific Officer. A prodrug is a compound that is inactive until it is inside a human body, where metabolic processes convert it into an active drug.


New Startup Changing The Game

July 20, 2016

Evestra announced today that a new publication describing estradiol prodrugs that lack liver side effects and offer the chance to replace ethinyl estradiol as the estrogenic component of contraceptive products will be published in Journal of Steroid Biochemistry & Molecular Biology 165 (2017) 305-311

“Estradiol prodrugs (EP) for efficient oral estrogen treatment andabolished effects on estrogen modulated liver functions”

W. Elger, R. Wyrwa, G. Ahmed, F. Meece, H.B. Nair, B. Santhamma, Z. Kileen, B. Schneider, R. Meister, H. Schubert, K. Nickisch